What happened with SNWV today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
SANUWAVE Health, Inc. supplies healthcare providers with UltraMIST, a system that delivers low-frequency ultrasound through a fluid mist without direct contact with the wound. It is FDA-cleared for wound healing and removal of damaged tissue across various acute and chronic wounds. Treatment must be administered by a healthcare professional.
UltraMIST is the company’s only currently marketed commercial product and accounts for nearly all revenue. Customers buy systems, primarily in the United States, through direct sales, distributors and resellers. Each treatment uses a new sterile applicator, so continued use of installed systems generates repeat purchases of consumables, its largest revenue source.
Demand depends partly on insurance coverage and reimbursement for wound care. Production also relies on outside suppliers: Nortech Systems supplies generator and treatment-wand components, while Dynamic Group manufactures applicators and kits. Most component materials come from single suppliers, and a single supplier assembles all finished products, making continuity of supply important.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
SANUWAVE’s results hinge on UltraMIST adoption and recurring applicator use, with Organogenesis, NanoVibronix and privately held Arobella Medical also worth watching for competition.
MiMedx Group sells wound-treatment grafts to U.S. clinicians treating the same advanced wound-care patients SANUWAVE targets with UltraMIST ultrasound. Its U.S. wound-treatment sales are more relevant to that competition than its surgical or burn applications.
Solventum sells providers systems that apply suction to wounds—negative-pressure wound therapy—and advanced dressings that they can use alongside or instead of SANUWAVE’s UltraMIST. Watch those wound-care products within MedSurg rather than treating Solventum’s overall sales as a measure of competition.
Smith & Nephew competes with SANUWAVE for providers’ advanced wound-care treatment choices while selling a much broader range of medical technologies and services. Its work with healthcare customers on clinical evidence and reimbursement is worth watching because those factors also shape providers’ choice of UltraMIST.
Bioventus competes directly for wound-care providers’ treatment choices: its SonicOne uses ultrasound to remove tissue from wounds, while SANUWAVE offers UltraMIST ultrasound wound treatment.
SANUWAVE depends on Nortech Systems to manufacture the generator and treatment-wand components for UltraMIST, then tests those components itself. Nortech’s ability to keep supplying those parts matters to SANUWAVE’s production, which the company says could be disrupted by losing a supplier.
Integra LifeSciences sells tissue-repair products that compete with SANUWAVE for providers’ advanced wound-care treatment choices. Watch its Tissue Technologies business for that competition, since most of Integra’s revenue comes from specialty surgical products.
Celularity sells placenta-derived materials for wound care that compete for treatment spending with SANUWAVE, which bought the UltraMIST business from Celularity in 2020. Watch Biovance 3L and Rebound sales in its wound-care and degenerative-disease business for the current competitive tie.
Sonoma Pharmaceuticals sells hypochlorous-acid wound-care products to providers treating wounds that SANUWAVE addresses with non-contact ultrasound. Its wound-care sales and distribution partnerships are the relevant signals, rather than its eye-care, animal-health or disinfectant businesses.
Fed Interest Rate Decision
SANUWAVE’s Fed-linked borrowing costs can rise or fall with interest rates, changing how much cash its $23.0 million secured term loan and revolving facility leave for its wound-care business.
Expected4.0%Last release4.0%
If it comes in above expectations
If the Fed signals higher rates than expected, interest on borrowing tied to SOFR or a floating rate may cost SANUWAVE more, leaving less cash for making UltraMIST systems and applicators available to care facilities.
If it comes in below expectations
If the Fed signals lower rates than expected, borrowing tied to SOFR or a floating rate may cost SANUWAVE less, leaving more cash available to supply UltraMIST systems and applicators to care facilities.
Bioventus Inc. earningsBVS
Bioventus’s report will show whether wound-care providers are buying more of its products, including SonicOne, an ultrasound system that competes with SANUWAVE’s UltraMIST for treatment choices.
Read Bioventus’s wound-care sales alongside any disclosure about SonicOne use. Stronger sales with rising SonicOne use would show providers buying a competing ultrasound approach to wound treatment, increasing competition for SANUWAVE’s treatment choices; weaker sales or stalled use would signal less traction for this rival, not prove that demand for UltraMIST is rising.
SANUWAVE Health, Inc. earningsThis company
SANUWAVE’s report will show whether sales of the single-use applicators required for each treatment are keeping pace with UltraMIST system sales.
Read UltraMIST consumables revenue alongside system revenue and the share left after product costs. If consumables grow with systems, repeat sales from treatment use are building; if system revenue rises while consumables lag and the share left after costs narrows—especially as reseller sales weigh on system prices—system sales are not yet translating into enough recurring consumables revenue.
